Free PSA is best marker for prostate cancer:
This article was originally published in Clinica
Free PSA is a better diagnostic of malignancy in prostate cancer than the alternatives of age-specific PSA testing and PSA density calculation, according to a paper in this month's Urology. In the study, the Beckman Coulter Hybritech free-PSA test was found to be have the same sensitivity (95%) as a PSA density measurement, while also being less expensive because it does not need an ultrasound scan. The age-specific reference method was found to be less sensitive than free PSA, missing between 20% and 60% of cancers in men over 60 years old.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.